NEW YORK, July 24, 2015 /PRNewswire/ -- Americord Registry, a private cord blood, cord tissue, and placenta tissue banking company, announced today that it has seen continued strong quarterly growth through the second quarter of 2015.
"We saw a spike in quarterly growth at the beginning of 2015," said Americord CEO Martin Smithmyer. "We're thrilled that we've been able to carry that through to the second quarter and we have promising projections for continued growth and increased revenue throughout the remainder of 2015."
At the close of the first quarter of this year, Americord reported 50 percent quarterly growth and has continued that trend with 30 percent quarterly growth at the close of the second quarter.
"We are building on several years of strong growth," said Smithmyer. "We've demonstrated 1,200 percent growth in the last three years and we are still continuing that trend." Americord has secured a spot on this year's Inc. 5000 due to considerable growth in past years. "Our continued success indicates that we are still gathering market share in this competitive industry and our placement on the Inc. 5000 reinforces our trajectory."
About Americord Registry
Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord and its affiliate lab, Cook General Biotechnology collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry's website at http://www.americordblood.com for more information.
866-503-6005 ext. 944
SOURCE Americord Registry